Breast Diseases Clinical Trials

Completed

Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

NCT00065533

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician. Buenos Aires, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician. Capitol Federal, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician. S.M. de Tucuman, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician. San Miguel de Tucumán, Argentina

View all 19 locations

View Trial Details

Completed

Tamoxifen-MRI Study

NCT00295100

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: UCLA Medical Center Los Angeles, California, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

Wayne State University Detroit, Michigan, United States

Mayo Clinic Rochester, Minnesota, United States

View Trial Details

Completed

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

NCT00191438

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Saint-Herblain, France

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Heidelberg, Germany

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Naples, Italy

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Arnhem, Netherlands

View Trial Details

Completed

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

NCT00190697

Conditions: Adnexal Diseases, Breast Cancer, Breast Diseases, +22 more
Locations: For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician Houston, Texas, United States

View Trial Details

Completed

Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

NCT00114816

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: Department of Oncology, Helsinki University Central Hospital, Finland Helsinki, Finland

View Trial Details

Completed

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

NCT00080041

Conditions: Adnexal Diseases, Breast Diseases, Breast Neoplasms, +26 more
Locations: University of Rochester Cancer Center Rochester, New York, United States

View Trial Details

Completed

A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer

NCT00051051

Conditions: Breast Diseases, Breast Neoplasms, Neoplasms, +3 more
Locations: Pfizer Investigational Site Montgomery, Alabama, United States

Pfizer Investigational Site Arroyo Grande, California, United States

Pfizer Investigational Site Montebello, California, United States

Pfizer Investigational Site San Francisco, California, United States

View all 66 locations

View Trial Details

Completed

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

NCT00034827

Conditions: Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +24 more
Locations: Pfizer Investigational Site Birmingham, Alabama, United States

Pfizer Investigational Site Birmingham, Alabama, United States

Pfizer Investigational Site Blendora, California, United States

Pfizer Investigational Site Glendale, California, United States

View all 30 locations

View Trial Details

Completed

Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer

NCT00160901

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +4 more
Locations: Department of Complementary and Integrative Medicine Heidelberg, Baden-Wurttemberg, Germany

View Trial Details

Completed

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

NCT00234195

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +9 more
Locations: Thomas Jefferson University, Department of Psychiatry Philadelphia, Pennsylvania, United States

View Trial Details

Breast Diseases

Breast Diseases trial results

Related conditions